PMID- 24100387
OWN - NLM
STAT- MEDLINE
DCOM- 20140724
LR  - 20180822
IS  - 1440-1711 (Electronic)
IS  - 0818-9641 (Linking)
VI  - 91
IP  - 10
DP  - 2013 Nov-Dec
TI  - Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain 
      antibody.
PG  - 615-24
LID - 10.1038/icb.2013.45 [doi]
AB  - The efficacy of immunotherapy based on natural killer (NK) cells is hampered by 
      intrinsic non-specific cytotoxicity and insufficient activation of NK cells. 
      Here, we confer the T-cell receptor-like (TCR-like) specificity on NK cells, 
      taking advantage of both the innate and adaptive immune arms of the immune 
      response to generate enhanced anti-melanoma activity. The TCR-like antibody (Ab) 
      GPA7 was selected against melanoma-associated gp100/human leukocyte antigen 
      (HLA)-A2 complex and then fused to intracellular domain of CD3-zeta chain. This 
      fusion construct was incorporated into NK-92MI cell line and expressed as a 
      chimeric antigen receptor on the surface of the cell. The anti-tumour activity of 
      the transgenic NK-92MI-GPA7-zeta cell line was assessed against melanoma in vitro 
      and in vivo. The engineered NK-92MI-GPA7-zeta cells could recognize melanoma cells 
      in the context of HLA-A2 and showed enhanced killing of both melanoma cell lines 
      and primary melanoma. Furthermore, adoptively transferred NK-92MI-GPA7-zeta cells 
      significantly suppressed the growth of human melanoma in a xenograft model in 
      mice. Collectively, these results demonstrate that the TCR-like Ab, GPA7, could 
      redirect NK cells to target the intracellular antigen gp100 and enhance 
      anti-melanoma activity, providing a promising immunotherapeutic strategy to 
      prevent and treat melanoma.
FAU - Zhang, Ge
AU  - Zhang G
AD  - 1] The Centre for Molecular Immunology and China-Japan Joint Laboratory of 
      Molecular Immunology and Microbiology, Institute of Microbiology, Chinese Academy 
      of Sciences, Beijing, China [2] University of Chinese Academy of Sciences, 
      Beijing, China.
FAU - Liu, Rongzhi
AU  - Liu R
FAU - Zhu, Xuekai
AU  - Zhu X
FAU - Wang, Lei
AU  - Wang L
FAU - Ma, Juan
AU  - Ma J
FAU - Han, Huamin
AU  - Han H
FAU - Wang, Xiaomin
AU  - Wang X
FAU - Zhang, Ganlin
AU  - Zhang G
FAU - He, Wen
AU  - He W
FAU - Wang, Wei
AU  - Wang W
FAU - Liu, Changzhen
AU  - Liu C
FAU - Li, Shenghua
AU  - Li S
FAU - Sun, Meiyi
AU  - Sun M
FAU - Gao, Bin
AU  - Gao B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131008
PL  - United States
TA  - Immunol Cell Biol
JT  - Immunology and cell biology
JID - 8706300
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Single-Domain Antibodies)
SB  - IM
MH  - Animals
MH  - Antibody Specificity/immunology
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cytotoxicity, Immunologic
MH  - Humans
MH  - Melanoma/*immunology/pathology
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Protein Multimerization
MH  - Receptors, Antigen, T-Cell/*immunology
MH  - Single-Domain Antibodies/*immunology
MH  - Xenograft Model Antitumor Assays
EDAT- 2013/10/09 06:00
MHDA- 2014/07/25 06:00
CRDT- 2013/10/09 06:00
PHST- 2013/06/29 00:00 [received]
PHST- 2013/08/01 00:00 [revised]
PHST- 2013/08/01 00:00 [accepted]
PHST- 2013/10/09 06:00 [entrez]
PHST- 2013/10/09 06:00 [pubmed]
PHST- 2014/07/25 06:00 [medline]
AID - icb201345 [pii]
AID - 10.1038/icb.2013.45 [doi]
PST - ppublish
SO  - Immunol Cell Biol. 2013 Nov-Dec;91(10):615-24. doi: 10.1038/icb.2013.45. Epub 
      2013 Oct 8.